Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Astrazeneca Plc ADR (AZN)

Astrazeneca Plc ADR (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Alibaba Was the Market’s Favorite Chinese AI Stock in 2025: What’s BABA’s 2026 Forecast?

Chinese stocks had a strong year and are set to outperform the U.S. markets in 2025. The rally in Chinese stocks, which began last year after the country started unleashing stimulus measures, gained traction this year. While the artificial intelligence (AI) euphoria faded in the U.S. and the “Magnificent 7” did not have that magnificent a performance in 2025, the fever caught up with Chinese stocks. Alibaba (BABA) emerged as the preeminent AI play in the world’s second-largest economy. The stock, which was once “uninvestable” for being in the wrong books of Chinese authorities, saw a near FOMO trade this...

Fundamentals

See More
  • Market Capitalization, $K 286,946,304
  • Shares Outstanding, K 3,101,452
  • Annual Sales, $ 54,073 M
  • Annual Income, $ 7,035 M
  • EBIT $ 12,801 M
  • EBITDA $ 19,489 M
  • 60-Month Beta 0.31
  • Price/Sales 5.33
  • Price/Cash Flow 14.76
  • Price/Book 6.27

Options Overview Details

View History
  • Implied Volatility 24.60% (unch)
  • Historical Volatility 17.56%
  • IV Percentile 53%
  • IV Rank 18.22%
  • IV High 47.30% on 04/08/25
  • IV Low 19.54% on 08/14/25
  • Expected Move (DTE 17) 3.02 (3.27%)
  • Put/Call Vol Ratio 1.85
  • Today's Volume 605
  • Volume Avg (30-Day) 3,529
  • Put/Call OI Ratio 0.79
  • Today's Open Interest 124,501
  • Open Int (30-Day) 136,153
  • Expected Range 89.36 to 95.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.09
  • Number of Estimates 5
  • High Estimate 1.18
  • Low Estimate 1.03
  • Prior Year 1.05
  • Growth Rate Est. (year over year) +3.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
89.28 +3.64%
on 12/12/25
93.10 -0.61%
on 12/23/25
-0.19 (-0.20%)
since 11/28/25
3-Month
80.48 +14.97%
on 11/04/25
94.01 -1.58%
on 11/26/25
+15.81 (+20.61%)
since 09/30/25
52-Week
61.24 +51.09%
on 04/09/25
94.01 -1.58%
on 11/26/25
+26.96 (+41.12%)
since 12/30/24

Most Recent Stories

More News
Alibaba Was the Market’s Favorite Chinese AI Stock in 2025: What’s BABA’s 2026 Forecast?

Alibaba established itself as a preeminent AI play in China this year, which helped support its rally. The 2026 outlook also looks reasonably good after the recent fall.

BABA : 147.79 (-0.47%)
AAPL : 272.87 (-0.33%)
AZN : 92.54 (+0.02%)
BMWKY : 36.6900 (-0.27%)
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer

Tenth Breakthrough Therapy Designation for AstraZeneca and Daiichi Sankyo’s ENHERTU with the latest based on DESTINY-Breast05 Phase III trial results

AZN : 92.54 (+0.02%)
When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology

Market rotations are as old as Wall Street itself. When capital exits overheated sectors like big tech, it often finds its way into undervalued industries ripe for rediscovery. The latest shift, away from...

AZN : 92.54 (+0.02%)
PPCB : 0.5800 (-0.99%)
RHHBY : 51.7130 (-0.17%)
BMY : 53.99 (-0.22%)
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer

Based on DESTINY-Breast09 Phase III trial results that showed AstraZeneca and Daiichi Sankyo’s ENHERTU in combination with pertuzumab reduced the risk of disease progression or death by 44% vs. THP with...

AZN : 92.54 (+0.02%)
AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH

Investigational T-cell engager, surovatamig, and CAR T-cell therapy, AZD0120, will show potential with initial data across multiple blood cancers ...

AZN : 92.54 (+0.02%)
IonQ Wants to Bring Quantum Computing to Medicine. Should You Buy IONQ Stock Here?

With IonQ bringing quantum computing into healthcare, is now the time for investors to start paying attention to this stock?

NVDA : 187.82 (-0.21%)
AZN : 92.54 (+0.02%)
$SPX : 6,904.44 (-0.02%)
IONQ : 46.14 (+1.97%)
AMZN : 231.34 (-0.31%)
Vistagen Appoints Nick Tressler as Chief Financial Officer

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates...

SENS : 5.60 (-1.23%)
AZN : 92.54 (+0.02%)
VTGN : 0.6725 (+1.42%)
IMFINZI® approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers

Based on MATTERHORN Phase III trial results which showed a 29% reduction in the risk of progression, recurrence or death and a 22% reduction in the risk of death for the IMFINZI regimen vs. chemotherapy...

AZN : 92.54 (+0.02%)
AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth

New capacity at AstraZeneca’s Fredrick and Gaithersburg facilities will accelerate production of cancer, rare and chronic disease medicines Fourth...

AZN : 92.54 (+0.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition...

See More

Key Turning Points

3rd Resistance Point 93.39
2nd Resistance Point 93.14
1st Resistance Point 92.83
Last Price 92.54
1st Support Level 92.27
2nd Support Level 92.02
3rd Support Level 91.71

See More

52-Week High 94.01
Last Price 92.54
Fibonacci 61.8% 81.49
Fibonacci 50% 77.63
Fibonacci 38.2% 73.76
52-Week Low 61.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar